CGEM is the ticker symbol for Cullinan Therapeutics, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks CGEM with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is CGEM a good stock to buy?

CGEM is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/CGEM.

Where does 13F Pro source CGEM data?

All Cullinan Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cullinan Therapeutics, Inc. files with the SEC under CIK 1789972. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Cullinan Therapeutics, Inc. CGEM

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026

$1.30B total

MPM BioImpact LLC

$177.21M+27.2%

Lynx1 Capital Management LP

$163.23M0.0%

BVF INC/IL

$104.72M0.0%

BlackRock, Inc.

$95.29M+17.6%

PRICE T ROWE ASSOCIATES INC /MD/

$69.67M+88.5%

STATE STREET CORP

$66.81M+44.2%

Kynam Capital Management, LP

$56.71M0.0%

VANGUARD CAPITAL MANAGEMENT LLC

$47.60M+5.3%

RTW INVESTMENTS, LP

$43.05M+38.6%

Siren, L.L.C.

$34.48M+58.7%

GEODE CAPITAL MANAGEMENT, LLC

$28.18M+13.1%

Blue Owl Capital Holdings LP

$28.04M-19.4%

VR Adviser, LLC

$25.13M0.0%

BOOTHBAY FUND MANAGEMENT, LLC

$19.71M-2.7%

DIMENSIONAL FUND ADVISORS LP

$19.06M+15.5%

GOLDMAN SACHS GROUP INC

$18.24M+119.9%

Affinity Asset Advisors, LLC

$15.95M+12.1%

VANGUARD PORTFOLIO MANAGEMENT LLC

$13.45M+33.7%

BOONE CAPITAL MANAGEMENT LLC

$12.83MNew

Elmind Capital, LP

$12.56M+30.2%

MORGAN STANLEY

$11.45M+6.7%

TWIN FOCUS CAPITAL PARTNERS, LLC

$10.84M0.0%

AQR CAPITAL MANAGEMENT LLC

$10.59M+61.1%

NORTHERN TRUST CORP

$10.40M+27.1%

BANK OF AMERICA CORP /DE/

$9.29M-1.2%

See all 184 institutional holders →

Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CGEM

Earnings Per Share

13fpro.ai/company/CGEM

Loading ratio trend…

CGEM key financials by period

Reported revenue, net income and operating margin by fiscal year, from Cullinan Therapeutics, Inc.'s annual filings on SEC EDGAR.

Cullinan Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2021	10-K	$18.9M	$-65.6M	—

Source: CGEM filings on SEC EDGAR →

About Cullinan Therapeutics, Inc. (CGEM): stock profile, AI score and financials

Cullinan Therapeutics, Inc. (CGEM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CGEM is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of CGEM by reported 13-F value include MPM BioImpact, Lynx1 Capital Management, BVF, based on the most recent SEC filings. CGEM trades on the Nasdaq exchange and files with the SEC under CIK 1789972. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CGEM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cullinan Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1789972 →